Tyrosine Kinases as Druggable Targets in Cancer

Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Materyal Türü: Online
Dil:İngilizce
Baskı/Yayın Bilgisi: IntechOpen 2021
Konular:
Online Erişim:ONIX_20210420_9781789848090_2372
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
_version_ 1869527394536128512
collection Directory of Open Access Books
description Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment.
format Online
id doab-20.500.12854ir-67013
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher IntechOpen
publisherStr IntechOpen
record_format ojs
spelling doab-20.500.12854ir-670132024-03-31T22:43:37Z Tyrosine Kinases as Druggable Targets in Cancer Ren, Huan Oncology thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management. In this book, we examine a few aspects of PTKs and cancer, considering efficacy, predictive markers to therapeutic response, limitations, and future directions in TKI treatment. In this rapidly evolving field, overcoming therapeutic resistance is most challenging, and multi-targeting directs the next-generation TKIs and combination therapy as ongoing strategies in cancer treatment. 2021-04-20T16:00:12Z 2021-04-20T16:00:12Z 2019 book ONIX_20210420_9781789848090_2372 9781789848090 9781789848083 9781839622199 https://directory.doabooks.org/handle/20.500.12854/67013 eng image/jpeg n/a https://www.intechopen.com/books https://mts.intechopen.com/storage/books/8660/authors_book/authors_book.pdf IntechOpen IntechOpen 10.5772/intechopen.79884 10.5772/intechopen.79884 78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6 9781789848090 9781789848083 9781839622199 IntechOpen 134 open access
spellingShingle Oncology
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
Tyrosine Kinases as Druggable Targets in Cancer
title Tyrosine Kinases as Druggable Targets in Cancer
title_full Tyrosine Kinases as Druggable Targets in Cancer
title_fullStr Tyrosine Kinases as Druggable Targets in Cancer
title_full_unstemmed Tyrosine Kinases as Druggable Targets in Cancer
title_short Tyrosine Kinases as Druggable Targets in Cancer
title_sort tyrosine kinases as druggable targets in cancer
topic Oncology
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
topic_facet Oncology
thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology
url ONIX_20210420_9781789848090_2372